Standard BioTools reports Q4 EPS (9c), consensus (3c)

Reports Q4 revenue $46.72M, consensus $43.03M. “2024 was a year of execution and integration despite a dynamic economic backdrop. We have streamlined our operations, unified our business systems and strengthened our management team, establishing a foundation for the next phase of growth,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools (LAB). “Powered by SBS, we came in at the top end of our 2024 revenue guidance, exceeded our original cost synergy target by $10 million, now running at $90 million in just twelve months. We also drove continued efficiency gains, improving pro forma non-GAAP operating expenses by 22% and adjusted EBITDA by 33% year over year.”